137 related articles for article (PubMed ID: 23885463)
1. [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].
Levi Y; Barshack I; Avivi K; Bar-ILan D; Gutman M; Aderka D; Berger R; Yacobi R
Harefuah; 2013 Jun; 152(6):326-9, 369. PubMed ID: 23885463
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
[TBL] [Abstract][Full Text] [Related]
4. Beyond the KRAS test.
Laurent-Puig P; Lièvre A; Blons H
Eur J Cancer; 2009 Sep; 45 Suppl 1():398-9. PubMed ID: 19775645
[No Abstract] [Full Text] [Related]
5. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
6. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
7. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
8. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
[TBL] [Abstract][Full Text] [Related]
9. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
10. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
11. Amphiregulin and epiregulin expression in neoplastic and inflammatory lesions in the colon.
Nishimura T; Andoh A; Inatomi O; Shioya M; Yagi Y; Tsujikawa T; Fujiyama Y
Oncol Rep; 2008 Jan; 19(1):105-10. PubMed ID: 18097582
[TBL] [Abstract][Full Text] [Related]
12. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
14. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
15. Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
Williams CJM; Elliott F; Sapanara N; Aghaei F; Zhang L; Muranyi A; Yan D; Bai I; Zhao Z; Shires M; Wood HM; Richman SD; Hemmings G; Hale M; Bottomley D; Galvin L; Cartlidge C; Dance S; Bacon CM; Mansfield L; Young-Zvandasara K; Sudan A; Lambert K; Bibby I; Coupland SE; Montazeri A; Kipling N; Hughes K; Cross SS; Dewdney A; Pheasey L; Leng C; Gochera T; Mangham DC; Saunders M; Pritchard M; Stott H; Mukherjee A; Ilyas M; Silverman R; Hyland G; Sculthorpe D; Thornton K; Gould I; O'Callaghan A; Brown N; Turnbull S; Shaw L; Seymour MT; West NP; Seligmann JF; Singh S; Shanmugam K; Quirke P
Clin Cancer Res; 2023 Oct; 29(20):4153-4165. PubMed ID: 37363997
[TBL] [Abstract][Full Text] [Related]
16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
17. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
Jonker DJ; Karapetis CS; Harbison C; O'Callaghan CJ; Tu D; Simes RJ; Malone DP; Langer C; Tebbutt N; Price TJ; Shapiro J; Siu LL; Wong RP; Bjarnason G; Moore MJ; Zalcberg JR; Khambata-Ford S
Br J Cancer; 2014 Feb; 110(3):648-55. PubMed ID: 24335920
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway.
Panigone S; Hsieh M; Fu M; Persani L; Conti M
Mol Endocrinol; 2008 Apr; 22(4):924-36. PubMed ID: 18187604
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
20. Expression of epiregulin and amphiregulin in the rat ovary.
Sekiguchi T; Mizutani T; Yamada K; Kajitani T; Yazawa T; Yoshino M; Miyamoto K
J Mol Endocrinol; 2004 Aug; 33(1):281-91. PubMed ID: 15291759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
